During the opening segment of this panel discussion about recent advances and pharmacoeconomic considerations in the clinical management of Castration-Resistant Prostate Cancer (CRPC), discussion moderator Raoul S. Concepcion, MD, is joined by expert panelists David Crawford, MD, Jeffrey D. Dunn, PharmD, MBA, Michael Kolodziej, MD, and David Quinn, MD.
After the panelists briefly introduce themselves and explain their relationships to medical oncology, Dr Concepcion cites important statistics about the economic and clinical burden of CRPC.
Dr Quinn reviews the treatment landscape for CRPC and explains how a paradigm shift in the US Food and Drug Administration’s approval of agents to treat CRPC has improved the disease’s outlook.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Posters Detail Effects—and Uncertainty—of Drug Pricing Negotiations
May 7th 2024Research into the Inflation Reduction Act evaluated payer concerns, patient and physician behavior, which patients will benefit from the first 10 drugs selected for price negotiation, and the ripple effect into Medicaid at the state level.
Read More